Eng C, Kim T, Bendell J, Argilés G, Tebbutt N, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal N, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F, Investigators I, Ahn J, Asselah J, Badarinath S, Baijal S, Begbie S, Berry S, Canon J, Carbone R, Cervantes A, Cha Y, Chang K, Chaudhry A, Chmielowska E, Cho S, Chu D, Couture F, Cultrera J, Cunningham D, Van Cutsem E, Cuyle P, Davies J, Dowden S, Dvorkin M, Ganju V, Garcia R, Kerr R, Kim T, King K, Kortmansky J, Kozloff M, Lam K, Lee J, Lee A, Lesperance B, Luppi G, Ma B, Maiello E, Mandanas R, Marshall J, Marx G, Mullamitha S, Nechaeva M, Park J, Pavlakis N, Ponce C, Potemski P, Raouf S, Reeves J, Segal N, Siena S, Smolin A, Streb J, Strickland A, Szutowicz-Zielinska E, Tabernero J, Tan B, Valera J, Van den Eynde M, Vergauwe P, Vickers M, Womack M, Wroblewska M, Young R. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology 2019, 20: 849-861. PMID: 31003911, DOI: 10.1016/s1470-2045(19)30027-0.Peer-Reviewed Original Research